Table 2. Functional Outcome Per Implant Type for Metastatic Humerus (%).
|
Author, year |
Implant |
Follow-up (Months) |
Patients |
Outcome measure |
Median score (Range) |
|
Scotti, C. et al (2008) |
EPR |
30 |
40 |
MSTS |
73.1a (69.9-76.3) |
|
Cannon CP et al (2009) |
EPR |
24 |
67 |
MSTS |
63a(40-83) |
|
Piccioli A et al (2010) |
EPR IMN |
8 |
26 57 |
MSTS |
73a 79a |
|
Raiss, P. et al (2010) |
EPR |
38 |
30 |
MSTS |
19a(7-27) |
|
Griffiths, D. et al (2011) |
EPR |
71 |
30 |
MSTS |
72.3a(53.3- 100) |
|
Choi ES et al (2016) |
IMN |
14.2 |
32 |
MSTS |
27.7a(27.0-28.5) |
|
Pruksakorn D et al (2015) |
ERP |
16 |
16 |
MSTS |
33-77 |
|
Siegel, H.J. et al (2010) |
ORIF |
17.6 |
23 |
MSTS |
94.6 a(86-99) |
MSTS, musculoskeletal tumor society score; EPR, endoprosthesis; IMN, intramedullary nail; ORIF, open reduction internal fixation.
a Mean score.